Core Viewpoint - The company has initiated a Phase I single ascending dose (SAD) study for LAE103, a self-developed ActRIIB monoclonal antibody, in Australia, with the first subject having completed dosing [1] Group 1: Study Details - The SAD study is a randomized, double-blind, placebo-controlled trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 administered subcutaneously in healthy overweight or obese subjects [1] - The company aims to release the top-line data from this SAD study in the third quarter of 2026 [1] Group 2: Therapeutic Focus - The company is committed to introducing this precision therapy into areas of significant unmet medical needs in cardiovascular and metabolic diseases, such as obesity, sarcopenia, and heart failure [1]
来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药